Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects
Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Nathan Ford(World Health Organization), Peter Ehrenkranz(Gates Foundation), Surbhi Modi, Elliot Raizes(Botswana Harvard AIDS Institute Partnership), Saye Khoo(University of Liverpool), Jacque Wambui(National HIV/AIDS/STI/TB Council), Kenly Sikwese(Advisory Board Company (United States)), Anton Pozniak, Claire Thorne(University College London), Andrew Hill(University of Liverpool), Heather Watts(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Imelda Mahaka, Polly Clayden, Andrea Ciaranello(Harvard University), George K. Siberry(Columbia University Irving Medical Center), Meg Doherty(World Health Organization), Andrew Phillips(Wake Forest University), Ade Fakoya(British HIV Association), Cynthia A. Moore(Chesapeake Public Schools)
Cited by 43
Related Papers
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Prevention of Neural-Tube Defects with Folic Acid in China
|New England Journal of Medicine|1999|1.3k